Leadership Appointments at RQM+
August 28, 2024Research and Development AI and ML, Corporate, RQM+, appointment
Ronnie Mahofski and Kevin Rowland both become Executive Vice President and General Manager On August 27, MedTech service provider RQM+ announced …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
August 27, 2024Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …
New gastric & gastro-oesophageal junction cancer treatment VYLOY™ ▼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain
August 16, 2024GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer
Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …
First oral treatment for hormone-sensitive prostate cancer recommended by NICE
August 15, 2024Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer
Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …
FDA approves drug for primary biliary cholangitis
August 15, 2024Research and Development FDA Approval, FDA approva;, Hepatology, liver, primary biliary cholangitis
Accelerated approval has been granted for Gilead Science’s Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) by the US Food …
Kerato Ltd Partners with University of Montreal to develop novel treatment for corneal damage
August 14, 2024Research and Development Kerato, Opthalmology, University of Montreal, corenas
BSF the Main Market listed biotech company and owner of corneal tissue replacement company Kerato Ltd, is pleased to announce …
David Wheadon appointed to board of directors at Seaport Therapeutics
August 14, 2024Corporate, Seaport Therapeutics, appointment
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Verisense announce opening of Digital Biobank
August 14, 2024Research and Development AI, Devices, Diagnostics, Verisense, artificial intelligence, digital health, machine learning
This week, Verisense have announced that their Digital Biobank, with data from over one million people, is open for business.
China CDE clears Phase 3 Study of Lisafltoclax in Newlly Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome
August 13, 2024Clinical Research, Research and Development Ascentage Pharma, Oncology
The China Centre for Drug Evaluation (CDE) has cleared the registrational phase 3 study of lisaftoclax in combination with azacitadine …
Pfizer releases results for severe RSV-associated LRTD treatment study
August 13, 2024Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …
First Nasal Spray for Treatment of Anaphylaxis approved by FDA
August 12, 2024Research and Development Emergency Medicine, FDA, anaphylaxis, epinephrine, nasal
ARS Pharmaceuticals has been granted approval by the US Food and Drug Administration (FDA) for their epinephrine nasal spray, neffy, …
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
August 12, 2024Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells
Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …
Richmond promotes new Director of Communications and Participant Engagement
August 9, 2024Research and Development Corporate, Richmond Pharmacology, appointment, pharmaceutical
Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and …
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
August 9, 2024Research and Development Haematology, Janssen, New England Journal of Medicine, Obstetrics & Gynaecology, foetus, newborn, women's health
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …
Cresset collaborates with global leaders Enamine to enable the design of new Targeted Protein Degraders
August 9, 2024Research and Development Corporate, Cresset, Cressete, Enamine, Microbiology, Targeted Protein Degraders
This week, drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research …
Pharma services boom in China as CPHI & PMEC China posts record attendance
August 8, 2024Conferencing, Events & Incentives, Public Relations, Sales and Marketing CPHI China, PMEC China, pharma
Domestic and international markets in Asia surging as CPHI & PMEC China welcomes a staggering 93,000 attendees 08 August, 2024, …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
August 7, 2024Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …
Sangamo Therapeutics and Genentech team up to develop genomic medicines for neurodegenerative diseases
August 7, 2024Research and Development Genentech, Neurology, Sangamo Therapeutics, genomic medicine, neurodegenerative diseases
Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
August 6, 2024Research and Development Cardiac, Cardiology, Pfizer
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …
Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment
August 6, 2024Research and Development Levicept, Rheumatology, osteoarthritis, trial
Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for the treatment of osteoarthritis.
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
